Table 2.

Echocardiography and NT-proBNP measurements

Measurement	CoQ10 group [n = 19]					Placebo group [n = 20]
	Baseline	4 months	Difference	95% CI	p-Value	Baseline	4 months	Difference	95% CI	p-Value
LV EF, %	59.1 ± 6.1	61.6 ± 10.2	+2.6 ± 7.17	(− 6.26, +1.38)	0.194	59.3 ± 6.1	61.7 ± 8.5	+2.4 ± 8.73	(− 6.68, +1.73)	0.233
Lateral e', m/s	0.076 ± 0.027	0.08 ± 0.02	+0.04 ± 0.02	(− 0.015, +0.011)	0.795	0.086 ± 0.029	0.98 ± 0.023	+0.89 ± 2.71	(− 2.2, +0.42)	0.256
Lateral E/e', ratioa	12.57 ± 5.08	11.72 ± 5.70	− 0.86 ± 6.57	(− 2.64, +4.36)	0.609	8.10 ± 3.11	8.28 ± 4.50	+0.18 ± 3.76	(− 1.99, +1.62)	0.833
Difference in lateral E/e', ratio	− 0.86 ± 6.57					+0.18 ± 3.76				0.561
E/A, ratio	1.48 ± 0.95	1.69 ± 1.05	+0.21 ± 0.65	(− 0.57, +0.15)	0.231	1.19 ± 0.91	1.21 ± 0.87	+0.02 ± 0.44	(− 0.26, +0.22)	0.864
LV EDD, mm	47.5 ± 4.4	46.8 ± 4.1	− 0.76 ± 3.13	(− 0.85, +2.38)	0.329	47.8 ± 5.8	48.7 ± 6.0	+0.9 ± 2.96	(− 2.32, +0.53)	0.204
LV mass index, g/m2	95.8 ± 24.7	90.0 ± 14.7	− 5.8 ± 18.98	(− 3.99, +15.52)	0.229	100.6 ± 28.8	94.5 ± 32.5	+6.1 ± 23.41	(− 5.12, +17.4)	0.267
NT-proBNP, pg/mLb	767 (246–1714)	695 (306–1903)	− 370 ± 1819	(− 1339, +599)	0.717	511 (125–1318)	469 (119–1588)	− 147 ± 682	(− 497, +903)	0.163
Difference in NT-proBNP, pg/mLb	– 370 ± 1819					− 147 ± 682				0.640

Data are expressed as mean ± SD, ratio, or median (interquartile range)

All patients were included in the final analysis according to the intention-to-treat principle

CI confidence interval, CoQ10 coenzyme Q10, EDD end-diastolic diameter, EF ejection fraction, LV left ventricle, NT-proBNP N-terminal pro-B-type natriuretic peptide

No significant differences between intragroup changes before and after treatment were observed

^aSignificant intergroup difference was observed only for the lateral E/e' ratio at baseline (p = 0.004) and 4 months (p = 0.0125)

^bTo convert NT-proBNP values to picomoles per liter, divide by 8.457